QIAGEN NV (QIA MU) stock market data APIs
€34.9908
1.38(3.9%)
as of March 20, 2026
Try our APIs with
free plan!
QIAGEN NV Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for QIA.MU.
Prev. Close
34.9908
Open
36.3679
High
36.5924
Low
34.876
52 wk Range
32.9312-47.19
Market Cap
10 941 M
EPS
0.55
Dividends (Yield)
0
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get QIAGEN NV data using free add-ons & libraries
Get QIAGEN NV Fundamental Data
QIAGEN NV Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: 0.5
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
QIAGEN NV News
New
Qiagen Announces Form 20-F Annual Report Filing for 2025 Results
VENLO, the Netherlands, March 20, 2026--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated...
Liquid Biopsy Products Market Report 2026-2031 Featuring Analysis of Roche, Illumina, Qiagen, MDxHealth, Novogen, BGI, Myriad Genetics and More
Company Logo Dublin, March 20, 2026 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Product Market Report: Trends, Forecast and Competitive Analysis to 2031" has been added to ResearchAndMarkets.com's offeri...
QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention
New study supports QuantiFERON-TB Gold Plus use in immunocompromised and other high-risk populations in various settings Findings show QuantiFERON testing is cost-effective compared with tuberculin sk...
Hologic's Women's Health Index Flags Alarming Gaps in STI Screening
Hologic’s HOLX fifth edition of the Global Women’s Health Index highlights a persistent screening gap for key preventable conditions. Developed in partnership with Gallup, the Index tracks progr...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
